Parexel on the Pulse: EU Clinical Trial Regulation (CTR)

Paul Bridges on the EU Clinical Trial Regulation (CTR)

Return to Insights Center

Related Insights

Article

Regulation pathway/strategy: Key considerations for foreign medical product registration in China

Jul 1, 2025

Article

Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023

Webinar

How to navigate China’s regulatory environment

Feb 15, 2023

Whitepaper

The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations

Mar 9, 2023

Playbook

Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Blog

Celebrating 40 Years of Rare Disease Progress: WODC Highlights

Jun 6, 2023

Blog

Population variability: important considerations in vaccine development

Jun 14, 2023

Whitepaper

How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU

Jun 28, 2023

Article

The technologies that are reshaping biotherapeutics manufacturing, an EU perspective

Jul 6, 2023

Related Insights

Article

Regulation pathway/strategy: Key considerations for foreign medical product registration in China

Jul 1, 2025

Article

Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023

Webinar

How to navigate China’s regulatory environment

Feb 15, 2023

Whitepaper

The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations

Mar 9, 2023

Playbook

Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Show more